Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-003 · Medication safety
MED-SGLT2-001: Expected early eGFR dip after SGLT2i
Expected early eGFR dip after SGLT2i. Evaluates SGLT2i recently initiated is true.
Active rulePriority 104Kidney engine v1.2.0
Condition
- All of:
- SGLT2i recently initiated == true
- reversible eGFR decrease present == true
- severe acute red flag == false
What it reports
- Message: An initial reversible eGFR decrease after SGLT2 inhibitor initiation is generally not by itself an indication to discontinue therapy; clinician review remains required.
Evidence
- R1KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO), 2024.Supports: CKD definition and chronicity CGA classification albuminuria confirmation risk prediction referral medication stewardship progression monitoring
Cases where this rule fires
Open a case to see this rule fire with real inputs, then change the values until it stops.
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.